Zynex, Inc. (NASDAQ:ZYXI) Q1 2024 Earnings Call Transcript

Zynex, Inc. (NASDAQ:ZYXI) Q1 2024 Earnings Call Transcript April 30, 2024

Zynex, Inc. beats earnings expectations. Reported EPS is $0.0003, expectations were $. ZYXI isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Good afternoon, ladies and gentlemen. And welcome to the Zynex First Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to Quinn Callanan from MZ North America. Please go ahead.

Quinn Callanan: Thank you, operator and good afternoon, everyone. Earlier today, Zynex released financial results for the first quarter ending March 31, 2024. A copy of the press release is available on the company’s website. Joining me on today’s call are Thomas Sandgaard, Chairman, President and Chief Executive Officer; Dan Moorhead, Chief Financial Officer; Anna Lucsok, Chief Operating Officer; and Donald Gregg, President of Zynex Monitoring Solutions. Before we begin, I’d like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events. We encourage you to review the company’s past and future filings with the SEC, including without limitation, the company’s 2023 Form 10-K and subsequent Form 10-Qs, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements.

These factors may include, without limitation, statements regarding product development, product potential, the regulatory environment, sales and marketing strategies, capital resources or operating performance. With that, I’ll now turn the call over to Thomas.

Thomas Sandgaard: Thank you, Quinn, and good afternoon, everyone. Thank you for joining us today for the first quarter 2024 earnings call. The first quarter was highlighted by ongoing revenue momentum, up 10% from the prior year, and being the eighth straight quarter of record high order numbers. Revenues of approximately $1 million was delayed in the quarter from the impact of change healthcare’s cyber event that presented a significant disruption to claims flow across the entire healthcare sector. Due to the event, payments from a large group of our payers were delayed, causing our revenue to come in slightly lower than expected. We expect to recognize that revenue over the rest of the year, and we are reaffirming the 2024 guidance of at least $227 million.

I also want to highlight that we had $2.1 million in positive cash from operations in the first quarter, an increase from the prior year. Our team continues to drive revenue higher and deliver significant earnings and free cash flows as we continue to expand our salesforce, investing in our new products in Zynex monitoring also combating wage inflation like many others in the industry. Our salesforce has continued to expand the market each quarter, enabled by a strong team and with a compelling product portfolio. The first quarter orders increased 23% year-over-year and we are confident that our sales team, as they continue to scale, that our revenue and earnings will continue to grow. To help drive the sort of growth, we received clearance from the FDA for our new M-Wave Neuromuscular Electrical Stimulation device, now in production and shipping to patients.

In addition to the impressive results from our profitable pain management division, CMS or Zynex Monitoring Solutions, continue to move forward in the first quarter with the further development of our blood and fluid monitor and our laser based pulse oximeter. We’re excited to announce FDA clearance last year for our second generation blood and fluid monitor and non-invasive and wireless technology targeted to improve patient outcomes with better fluid management in hospital settings. We continue to collect additional data in clinical trials and Don Greg will provide further updates on this product in his prepared remarks. In addition to our blood and fluid monitor, we have three other products in the pipeline in our pre-revenue hospital monitoring products division.

A laser based pulse oximeter called NICO, non-invasive co-oximeter, a monitor for early detection of sepsis and a non-invasive laser based monitor of total hemoglobin levels, the HemeOx. During the quarter, we continue to make strong progress for the NICO with several major device components and a verification study being now beginning in the middle of 2024. We now expect to submit an application to the FDA for our laser-based pulse oximeter in the fourth quarter of 2024 due to the timing of the verification study. Overall, we continue to make great progress in the patient monitoring division, which we believe will have game-changing growth potential for the company. Looking ahead, we are making significant progress building on our holistic, non-invasive approach with at home pain management devices and also diversifying with new products.

We are expanding our direct sales force that are delivering accelerating and high recurring revenue as we continue to execute operationally and strategically. In tandem, we are focused on ramping our hospital monitoring division, which represents a large growing market opportunity. We expect consistent growth and strong financial performance also in 2024, following the double-digit growth that we have produced year-over-year. We also expect additional catalysts and regulatory milestones during the year as we work to execute on our strong pipeline of new products. We look forward to additional updates in the months to come as we build our salesforce and execute on our growth objectives to improve the quality of life, our patients suffering from debilitating pain or illness, and bringing long-term value for our shareholders.

With that, I will now turn the call over to Anna Lucsok, our Chief Operating Officer for a more detailed business update.

Anna Lucsok: Thank you, Thomas. Zynex’s Pain Management Division has another impressive quarter with 20% order growth. Revenue grew 10% year-over-year, but was lower than expected due to the change healthcare cyberattack causing delays in payments from a large group of payers. The disruption caused by the cyberattack impacted our ability to submit claims and caused suspension and claim payments for several commercial payers. However, we expect to recover the shortfall over the remainder of 2024. As Thomas mentioned, we also received FDA clearance for the M-Wave, our next-generation NMES. The M-Wave is set to replace its predecessor, the E-Wave, which has been fundamental in NMES treatments across the U.S. since 1998. The E-Wave has helped thousands of patients with muscle-related issues such as drop-foot, quad rehabilitation, shoulder subluxation, and hand rehabilitation.

The M-Wave is designed to improve the way patients manage their neuromuscular conditions. With advanced features and a user-friendly design, the M-Wave allows patients to be treated in a clinical or home setting with ease. The compact and lightweight design of the M-Wave ensures portability and easy integration into patients recovery routine. The user-friendly interface and ease of use when designing a customer electrotherapy regimen will encourage an even broader adoption of our therapeutic products. NMES’ treatments have several uses, including adding recovery from surgery, managing chronic conditions, and even enhancing exercise performance in healthy individuals. We continue to refine our salesforce to maximize productivity and related profitability.

At the end of Q1, we had approximately 450 sales reps as we continue to hold reps to strict targets and exit under performers. We also continue to thoroughly screen new reps to ensure they meet the criteria, which we believe will make them successful. Having built the strong pipeline to prescribers to see patients in pain and in need of rehab, we are now focused on diversifying our revenue streams with our current line of rehabilitation products, which include low back support, bracing, cervical traction, and the recent additions of the Zynex Pro Hybrid LSO, a versatile 3-in-1 spinal orthosis, and the Zynex DynaComp cold compression that combines cold therapy and compression to accelerate recovery. Our expanded portfolio of rehabilitation products now makes up approximately 25% of all orders, up from 15% a couple years ago.

Revenue per rep on an annualized basis in Q1 was approximately $110,000, an increase of 7% over 2023. As our team continues to mature, we expect to drive sales efficiency higher. I look forward to another profitable year for the pain management division and updating you all on our market expansion and future calls. I’ll now ask Don Gregg, President of Zynex Monitoring Solutions, to provide updates related to that business division.

Donald Gregg : Thank you, Anna. With our monitoring products, we are looking to leverage this management team’s past success at building businesses to grow a second line of products with a much larger market opportunity to add comparable profitability. Zynex has the technologies and strategies necessary to make a successful entrance into this new product line, but acquiring FDA clearance is a unique process that many here at Zynex have experienced successfully traversing. The fluid monitoring product by our CM line of monitors is a precursor technology for our sepsis monitoring. Our CM technologies introduced to operating rooms entirely new capabilities that could alter the standard of care and ultimately improve the welfare of patients.

Recently, we completed important R&D milestones for the new CM-1700 development, measuring patient signals, and saw significant improvements over previous CM-1500 and 1600 devices. We are planning on upcoming clinical trial to demonstrate the improvements of the new hardware, and the first prototype for the CM-1700 is currently in design. We continue to consult with experts, key opinion leaders, and thought leaders in the space to refine the capabilities of our non-invasive products and ensure maximum uptake by potential future customers. We expect that building a successful standalone fluid monitoring market will be a longer-term effort than our other new monitoring products, but we believe strongly in the benefits patients will experience and the value proposition provided by the technology.

Our non-invasive laser pulse oximetry line, including NICO and HemeOx, continues progressing positively. We currently expect to submit NICO to the FDA in the fourth quarter of 2024, dependent on a successful verification study now being conducted in the second half of the year due to availability of our University Lab Partner. Our Lab Partner is a premier research institution in the area of oximetry. We are honored to be partnered with such a renowned institution and believe the results will help propel NICO toward FDA approval and oximetry improvements for society. As we prepare for NICO’s verification study, much of our focus has turned to our manufacturing capabilities. At this time, major components are on track to manufacture and produce NICO systems.

We are working diligently to engage experts, key opinion leaders, and professional societies to raise awareness of the science of laser pulse oximetry. We recently finalized our go-to -market strategy in this space, along with developing marketing execution strategies. Considering the competitive dynamics in this space, we refrain from detailing our initial go-to-market until closer to product launch. I will now turn the call over to Dan Moorhead, Chief Financial Officer, for a more in-depth look at financial performance for the quarter.

Dan Moorhead : Thanks, Don. Please refer to our press release issued earlier today for a summary of our financial results for the first quarter of 2024. After commenting on our financial results, Thomas will review our guidance for 2024. In the first quarter, orders increased 23% year-over-year to the highest number of orders in company history for the eighth consecutive quarter. Net revenue was $46.5 million compared to $42.2 million in the first quarter of 2023. Device revenue was $14 million compared to $11.9 million in the first quarter of last year. Supply’s revenue was $32.5 million, up from $30.2 million in the first quarter of last year. Gross profit in the first quarter was $37.2 million, or 80% of revenue, as compared to $32.9 million, or 78% of revenue in 2023.

Sales and marketing expenses were $23.4 million in the first quarter of 2024, compared to $21.2 million in the same period in 2023. G&A expenses were $13.3 million in the first quarter of 2024, compared with $7.4 million last year. Net income was $10,000 and produced $0.00 per deluded share in the first quarter of 2024 compared to net income of $1.6 million or $0.04 per deluded share in 2023. Adjusted EBITDA for the three months ended March 31st, 2024 was $1.7 million compared to $1 million in the quarter ended March 31st, 2023. We ended first quarter with $32.9 million of cash on the balance sheet and working capital of $56.2 million. Cash flows from operations in the three months ended March 31st, 2024 increased 7% year-over-year to $2.1 million.

In the first quarter we continued our stock buyback and repurchased 13.4 million of common stock and over the last 24 months we’ve purchased $78.5 million. We continue to balance deploying cash generated between investing in our business and returning cash to shareholders. We believe both offer attractive return profiles. The continuing buyback reflects our belief in our management team, the growth opportunities for both divisions, and that we remain committed to creating shareholder value in the near and long term. With that, I’ll turn the call back over to Thomas.

Thomas Sandgaard: Thank you, Dan. We’ve had a strong start to Q2 and with the continued growth in orders and with the delayed revenue recognition, we expect in the second quarter of 2024 to see revenue of $52 million, which is approximately 16% greater than the second quarter of 2023, and to see diluted earnings per share of $0.08 per share. As for our 2024 outlook, we expect total revenue to be approximately $227 million, representing a growth of approximately 23% over 2023, and diluted earnings per share of approximately $0.50 a share. We’re incredibly proud of the growth that we have consistently demonstrated over the past several years. Top-line revenue has produced high levels of profitability and free cash flows, which has allowed us to expand our salesforce, launch a new business to diversify our revenue stream, and continue to repurchase our shares in the open market.

The business we have created and the profitability we’re able to generate allows us a high degree of flexibility to allocate capital in several ways. We have the ability to continue investing in our business and return cash to shareholders simultaneously. We believe both these avenues will produce substantial shareholder value. And with that, operator, please open the call up for questions.

See also Jim Cramer is Recommending These 10 Stocks Heading Into May 2024 and Democrats and Corporate Insiders are Buying These 10 Stocks.

Q&A Session

Operator: [Operator Instructions] Your first question comes from Jeffrey Cohen of Ladenburg Thalmann.

Jeffrey Cohen: Good afternoon, everyone. How are you? Just a few questions from our end. So Thomas, did you call out $0.50 for the year and 277 on revenue? Any assumptions there on our future share repurchase, any commentary on April or balance of the year, and is some of that factored in when reaching out?

Thomas Sandgaard: Yes, it, I mean, obviously, orders grew well in the first quarter. We can see now that order’s grown in April compared to April of last year, approximately 25%. So we continue the cadence of order growth. We also see more and more; Anna was mentioning in the first quarter that our other products in the NexWave were up to 25%. It’s now sitting at around 27%, 28%. And we continue to grow the orders and the revenue from other products and just the NexWave, which overall is going to put us in a better position other than the products we obviously working on, creating diversification with the other division. So all-in-all, we find out into the years that we can be fairly confident on the $0.50 a share in terms of the bottom line and continue the revenue growth.

Jeffrey Cohen: Okay, got it. Can you talk a little bit about M-Wave being in production? It’s being, they’re being shipped out and are there shipments generally going for new users, new prescriptions or existing users?

Thomas Sandgaard: It’s all new prescriptions and in the past, we were, for those indications, we were getting the prescriptions for the E-Wave, which was a 25-year old product that was still in production. This, the M-Wave, which is largely replacing it, it’s a much easier to use. It also looks more elegant and it looks easy to use. The output performance is still basically making it the most powerful neuromuscular electrical stimulator on the market. And so it’s directly replacing that. The production is up and running. We have good inventory levels and everything looks just as it was planned on that product.

Jeffrey Cohen: Got it. Do you anticipate that M-Wave could become a material portion relative to NexWave over the next year or two?

Thomas Sandgaard: No, it’ll be the same ratio of what we see physicians prescribe. It’ll be just a few percent of our order production that won’t change. The NexWave is such a versatile product that when it’s, say, less complex neuromuscular electrical stimulation needs. It’s often something that the physician prescribes rather than going to the very versatile M-Wave.

Jeffrey Cohen: Okay, got it. I guess my last question is for you, Thomas, or Donald. Just talk about the hospital-based products and some timelines. It’s sounding like the NICO laser-based pulse ox could be first of the four to be commercial in the marketplace, and would you anticipate then that the blood-fluid monitor, 1700, when after going through some further analysis, would be concurrent to that or follow that perhaps in ‘25?

Thomas Sandgaard: Sure. I think, Jeff, a couple of things on this. One is that NICO is progressing well in its milestones. We’ve had a University Lab Partner doing our, preparing for our verification. We’ve had to move some dates with them. Therefore, we’re in the back half of the year. So NICO will be the first product that will be commercialized, and I think we’ve said this in the past that’s a 2025 revenue story. And there’s a product called HemeOx which is a derivative of that that adds a couple other important parameters that takes pulse oximetry into different care areas and call points due to those specific parameters. It is a follow-on product to NICO. It is similar to a commercialization strategy that the blood-fluid monitor is.

We achieved an important milestone last year with getting clearance for the CM-1600, and the CM-1700, its hardware is improved from both the 1500 and 1600. Therefore, we believe that’ll be a follow-on to the NICO commercialization. We’re in development of that at this point and then in specific clinical trials as we continue to prove out the fluid responsiveness of the signals in the system.

Jeffrey Cohen: So, I guess on the hemoglobin HemeOx could be earlier as compared to the CM-1700 and second in the pipeline or do you still feel that the blood fluid monitor would be second?

Thomas Sandgaard: I just want to give you some guidance Jeff that I think they’re probably similar. And we are working diligently on the technology of the NICO platform which enables both NICO and HemeOx. So, I don’t know if I have a full timing answer there for you, because we have real work to do in R&D on both of those, so.

Jeffrey Cohen: Okay. No, that’s certainly clear enough. I just wondered under that additional clarification. So, I think that does it for us. Thanks for taking the questions.

Operator: Your next question comes from Shagun Singh of RBC.

Unidentified Analyst: Hey, good afternoon. This is Abi for Shagun. Thanks for taking my questions. The first one is on the underperformance because of the cyberattack. He called out it was a $1 million revenue impact or so. Can you break out how much of that was in supplies and versus devices? And as a follow-up, is there anything that we should expect in Q2 for an impact?

Dan Moorhead : The breakouts are going to be similar to our normal breakout. So, the device supplies, we’re running kind of 25% to 30% on device and stops it that on supplies, so it should be similar to that. And Anna can comment on Q2.

Anna Lucsok: We’re expecting to recover from it throughout 2024, and we should start seeing the claims go through and recover throughout Q2 as well.

Unidentified Analyst: Okay, great. One last one for me. Can you update us on the strategic review process? Where are you in the process, if we can expect any news on that front, and you’ve potentially talked about going private, where are you on those conversations? Anything you can share would be great.